http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2010010371-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f05eb8fb1339358d0cd20a22b68b764 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 |
| filingDate | 2010-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12908105adfd766da8228fb94cdeba53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18c297f2b1b3fb10324682a33d4025e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40576ec9a58e0a0082abe7f85a3fb89d |
| publicationDate | 2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2010010371-A |
| titleOfInvention | EFFECT OF LOSARTAN ON THE PERIVASCULAR ADIPOSE TISSUE AND TREATMENT OF METABOLIC SYNDROME. |
| abstract | Recent studies have demonstrated the effect of perivascular adipose tissue (PVAT) in the regulation of vascular function, however its role in the metabolic syndrome model is unclear. The present invention relates to the use of losartan in the metabolic syndrome, particularly in the prevention of inhibition produced by chronic administration of fructase on the modulation that perivascular adipose tissue (PVAT) usually produces. The effect of losartan on PVAT derived from vascular dysfunction with hypertension was examined, which was induced by fructase in animal models. Rats used during the experiment were fed with water, 10% fructase, 10% fructase with losartan (10 mg / kg) for 8 weeks. In the isolated aorta with PVAT and endothelium, the contraction induced by norepinephrine (NE) was more potent in animals fed with fructase compared to control animals. Losartan use normalized blood pressure and insulin resistance and vasoconstriction induced by NE in animals fed fructase. According to the present invention, the use of losartan, for example, could be very useful in the treatment of patients with diabetes mellitus with poor circulation in the inner limbs, since this could correct the abnormal functioning of the PVAT. |
| priorityDate | 2010-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.